- STAT+: The sale of Watson Health assets ends a dark chapter for IBM. For its buyer, the opportunity looks brighterby Casey Ross on January 21, 2022
- STAT+: Up and down the ladder: The latest comings and goingsby Ed Silverman on January 21, 2022
- STAT+: Once billed as a revolution in medicine, IBM’s Watson Health is sold off in partsby Casey Ross on January 21, 2022
- STAT+: Pharmalittle: Alzheimer’s patient groups to protest Medicare plan for Biogen drug; cancer combo treatments are questionedby Ed Silverman on January 21, 2022
- Opinion: What genetic counselors can teach the CDC about communicating uncertaintyby Chenery Lowe and Liesl Broadbridge and Laynie Dratch on January 21, 2022
- Opinion: It’s staff, not stuff: Applying crisis standards of care to allocating health care workersby Cynda Hylton Rushton and Ian Wolfe and Tener Goodwin Veenema on January 21, 2022
- For doctors drowning in emails, one health system’s new strategy: pay for repliesby Mohana Ravindranath on January 21, 2022
- STAT+: If the Biogen CEO were truly ‘courageous,’ he would live with the Medicare decisionby Ed Silverman on January 21, 2022
- Listen: Biotech’s red tape, the latest billionaire science project, & a (possible) Omicron reprieveby Damian Garde and Meg Tirrell and Adam Feuerstein on January 20, 2022
- STAT+: New research casts doubt on how combination cancer therapies work in tandemby Angus Chen on January 20, 2022
- Kisses, licks, and drool: Study shows how ‘saliva sharing’ shapes babies’ understanding of the closest relationshipsby Andrew Joseph on January 20, 2022
- Opinion: To get to a ‘new normal,’ public health must focus on all respiratory virusesby Céline Gounder and Rick A. Bright and Ezekiel J. Emanuel on January 20, 2022
- STAT+: Pharmalittle: 27 companies will make generic Merck Covid pills; drug-resistant infections are deadlier than HIV or malariaby Ed Silverman on January 20, 2022
- After a flurry of firsts, xenotransplantation is suddenly back in the spotlightby Megan Molteni on January 20, 2022
- Opinion: This HIV prevention medicine is for everyone. Why do so few people take it?by Kathryn Macapagal on January 20, 2022
- Opinion: Researching collagen to help his achy knees, a statistician explores the painfully weak evidenceby Paul T. von Hippel on January 20, 2022
- Watch: In medicine, fax machines are still vital technologyby Alex Hogan on January 20, 2022
- ‘The scientists, they’re learning more’: A defiant Biden defends the CDC amid mounting criticismby Lev Facher on January 20, 2022
- Opinion: New global data showing 1.27 million deaths a year reveal the urgent need to address antimicrobial resistanceby Janet Midega on January 20, 2022
- Negative descriptors are more likely to appear in health records of Black patients, study findsby Elizabeth Preston on January 19, 2022